Roxana Matran | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Roxana Matran | Pharmacology | Best Researcher Award

Assist Prof Dr Roxana Matran, UMF “Carol Davila”, Romania

Dr. Roxana Matran is a distinguished pediatric gastroenterologist and academic with a Ph.D. from Carol Davila University of Medicine and Pharmacy (2017) 🎓. An Assistant Professor at the same university since 2019, she excels in teaching and research on pediatric pulmonology and gastroenterology. Her clinical expertise at “Grigore Alexandrescu” Emergency Hospital for Children includes contributions to groundbreaking clinical trials on inflammatory bowel diseases 🏥🔬. A dedicated volunteer with MD Caravana cu Medici 🤝, she brings healthcare to underserved communities. Dr. Matran’s active membership in ESPGHAN and advisory roles showcase her impactful influence in public health policy 🌍✨.

Publication Profile

orcid

Educational Backgrounds

Assist. Prof. Dr. Roxana Matran embarked on her academic journey at the prestigious Central School in Bucharest, where she specialized in Mathematics-Informatics with bilingual French instruction (📘✏️). She continued her education at “Carol Davila” University of Medicine and Pharmacy, earning a Bachelor’s Degree in 2009 (🎓🩺). Driven by her passion for medicine, she pursued a Ph.D. at the same university, completing her thesis on factors contributing to pulmonary disease in cystic fibrosis between 2013 and 2017 (📄🫁). Her dedication and expertise in the medical field have solidified her reputation as a leading academic and researcher in Bucharest (🌟🏥).

Work Experiance

Assist. Prof. Dr. Roxana Matran is a distinguished pediatric gastroenterologist and academic based in Bucharest. She serves as a member of the Advisory Committee on Post-Vaccination Adverse Reactions, analyzing vaccine-related health concerns (💉📊). She is also a sub-investigator in pivotal clinical trials, including studies on Vedolizumab and Adalimumab for pediatric Crohn’s disease and ulcerative colitis (🔬📑). Dr. Matran volunteers with Caravana cu Medici, offering medical consultations in underserved Romanian villages (🚑🤝). As an Assistant Professor at “Carol Davila” University, she teaches fifth-year medical students and conducts extensive research (📚👩‍🔬). Her work at “Grigore Alexandrescu” Emergency Hospital focuses on consultations, rounds, and clinical studies (🏥👶).

Membership

Assist. Prof. Dr. Roxana Matran is an active member of esteemed professional organizations in her field. Since June 2019, she has been a Full Member of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN), contributing to advancements in pediatric healthcare across Europe (🌍👶🩺). Additionally, she has been a dedicated member of the Romanian Society of Pediatrics since July 2016, working to promote excellence in pediatric medicine and research in her home country (🇷🇴📚💉). Her involvement in these societies underscores her commitment to improving children’s health and staying at the forefront of medical advancements (🌟🔬).

Conference and Seminars

Assist. Prof. Dr. Roxana Matran has an extensive track record of participation in prestigious medical events and specialized training programs worldwide. In 2024, she is set to attend the 5th Liver Transplant School in Brussels (25–28 September) and the ESPGHAN Mastercourse in Parenteral Nutrition in Linz, Austria (4–6 March). Her prior engagements include the ESPGHAN IBD Masterclass in Helsinki, Finland (2022) and the International Symposium on Pediatric Inflammatory Bowel Disease in Edinburgh, Scotland (2022). Over the years, she has honed her expertise in pediatric gastroenterology, nutrition, and pulmonology, attending courses in Italy 🇮🇹, Austria 🇦🇹, France 🇫🇷, and Greece 🇬🇷, and even completing a post-graduate program online 🌐.

Community Impact

Assist. Prof. Dr. Roxana Matran is deeply committed to serving underserved communities, demonstrating her passion for equitable healthcare access. She actively volunteers with MD Caravana cu Medici, a noble initiative providing essential medical consultations in impoverished Romanian villages 🏡. Through this work, Dr. Matran brings her expertise in pediatric gastroenterology and nutrition to those who need it most, offering care, guidance, and hope 🌟. Her dedication to improving public health goes beyond the clinic, reflecting a strong sense of compassion and responsibility toward marginalized populations 🤝. Dr. Matran’s efforts exemplify the true spirit of community service and medical care ❤️.

Clinical Expertise

Assist. Prof. Dr. Roxana Matran has made significant contributions to pediatric gastroenterology through her clinical practice, research, and involvement in clinical trials. As a pediatric gastroenterologist at “Grigore Alexandrescu” Emergency Hospital for Children 🏥, she seamlessly combines patient care with groundbreaking research. Dr. Matran has actively contributed as a subinvestigator for leading pharmaceutical companies, including Takeda Pharmaceuticals (VedolizumabSC-3003) and AbbVie (Adalimumab), advancing therapies for pediatric inflammatory bowel disease 🔬. She also researches post-vaccination adverse reactions as a member of the Advisory Committee at the Ministry of Health, ensuring better health outcomes for children globally 💉.

Research Focus

Dr. Roxana Elena Smădeanu’s research focus primarily revolves around pediatric health, with a special emphasis on diagnosing and managing complex diseases such as cystic fibrosis, intestinal tuberculosis, and respiratory conditions in children. Her work includes exploring microbiota’s role in functional abdominal pain disorders, respiratory symptomatology associated with COVID-19 in pediatric patients, and rare genetic syndromes like Menke-Hennekam syndrome. Additionally, her research delves into diagnostic methods like sweat conductivity in cystic fibrosis. This body of work aligns with clinical and laboratory research aimed at improving pediatric healthcare and diagnostics. 🧑‍🔬🩺👶

Publication Top Notes

Anti-Tumor Necrosis Factor-α Use in Pediatric Inflammatory Bowel Disease—Reports from a Romanian Center

Food Related Quality of Life in Children with Chronic Gastrointestinal Disorders: Comparative Study Between Inflammatory Bowel Disease and Celiac Disease—Reports from a Romanian Center

Anti TNF-a Use in Pediatric Inflammatory Bowel Disease – Reports from a Romanian Center

Quality of Life of Pediatric Patients with Chronic Intestinal, Liver, and Pancreatic Diseases During the COVID-19 Pandemic

Menke–Hennekam Syndrome: A Literature Review and a New Case Report

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Dr Michael Swedberg, Swedberg Preclinical Partner, Sweden

Dr. Michael Swedberg is a distinguished pharmacologist with extensive expertise in safety pharmacology, CNS pharmacology, gastrointestinal pharmacology, and drug abuse assessment. He has held key leadership roles, including Associate Director at AstraZeneca and founder of Swedberg Preclinical Partner AB. His global impact includes contributions to regulatory compliance, developing novel animal models, and mentoring future researchers. With a Ph.D. in discrimination learning and postdoctoral training at NIDA, Dr. Swedberg has collaborated internationally and received numerous accolades for his innovative research and leadership. His career embodies excellence in pharmacology and preclinical drug discovery. 🌍💊🔬

Publication Profile

scopus

Education

Dr. Michael Swedberg is a distinguished academic and researcher, having earned his Ph.D. in 1985 from the University of Uppsala, Sweden. His doctoral dissertation focused on “A Model of Discrimination Learning with Interoceptive Stimuli.” He completed his postdoctoral fellowship at the National Institutes of Health (NIH), specializing in addiction research at the National Institute on Drug Abuse’s Preclinical Pharmacology Branch in Baltimore, Maryland (1985–1988). Additionally, Dr. Swedberg holds a Bachelor of Social Science (B.S.Sc.) from Uppsala University, with a comprehensive background in psychology, sociology, and law. 🧠📚🎓

Professional Appointments

Dr. Michael Swedberg has had an extensive and distinguished career in pharmacology and drug discovery. From 2014 to 2021, he was the Founder and CEO of Swedberg Preclinical Partner AB in Sweden. Prior to that, he was a Partner and Consultant at The Research Network (TRN) from 2014 to 2016. His earlier career includes key roles at AstraZeneca R&D, where he served as Associate Director in Safety Pharmacology and Preclinical Development. He also held senior leadership positions at Novo Nordisk and Ferrosan. Dr. Swedberg’s journey began as a Lecturer at Mälardalen University in 1981. 🧑‍🔬💉📚

Academic Service

Dr. Michael Swedberg has made significant contributions to the field of pharmacology and neuroscience through various roles. He served as a board member for the Department of Psychology at the University of Uppsala and the Faculty of Social Sciences from 1980 to 1985. His leadership extended to chairing the Council of Graduate Students. Recognized for his service, Dr. Swedberg received awards from the Drug Abuse Liability Ad Hoc Committee and for his work with the Lilly–Novo Nordisk Muscarinic Research Collaboration. He has also been a grant evaluator for the European Union and Poland’s National Centre for Research and Development. 🌍🔬🧠

Presentations

Dr. Michael Swedberg has made significant contributions to the field of drug safety and abuse liability assessment. His research, presented at multiple prestigious meetings, includes the role of drug discrimination studies in evaluating novel compounds’ abuse potential. Notably, his work at the Safety Pharmacology Society, American College of Toxicology, and the Swedish Pharmaceutical Congress has advanced methodologies like rat self-administration and drug discrimination for psychoactive effects. His work on the interaction between mGluR5 antagonists and benzodiazepines also stands out. Swedberg’s contributions to safety pharmacology have had a lasting impact on CNS drug development and regulatory guidelines. 🧠💊

Lecturing and teaching

Dr. Michael Swedberg has delivered extensive lectures and seminars on safety pharmacology, drug abuse, and CNS risk assessment. His contributions include lectures at the American College of Toxicology, Safety Pharmacology Society, and the European Congress of Toxicologic Pathology, focusing on drug dependence, abuse liability, and CNS safety. Additionally, Swedberg has provided in-depth training on the regulatory and industrial challenges in drug development at AstraZeneca and other global platforms. His teaching spans from the biomedical program at Karolinska Institute to the University of Uppsala, covering neuropharmacology, psychopharmacology, and drug addiction. His educational materials are widely respected in the field. 🧠📚💊

Academic Supervision

Dr. Michael Swedberg has mentored numerous students at various stages of their academic careers, including graduate, Ph.D., and postdoctoral researchers. He supervised students at Umeå University, University of Uppsala, and Karolinska Institute, guiding experimental work in fields such as cannabinoid tolerance, dopamine release, and nicotine’s effects on learning. His postdoctoral supervision included projects on visual and auditory discrimination in drug testing. Swedberg’s research has been supported by multiple prestigious grants, such as the Clas Groschinsky Memorial Foundation and the Swedish Medical Research Council. His contributions have significantly advanced brain and behavior research. 🎓🧠💡

Committee Service

Dr. Michael Swedberg held several key roles at AstraZeneca, including membership in the Safety Knowledge Group for CNS and leadership in CNS GLP Safety Pharmacology Harmonization. He was also a part of multiple committees, such as the AstraZeneca Expert Advisory Group on Abuse Liability and the Cross Company Abuse Liability Consortium. Dr. Swedberg contributed to international organizations like PhRMA and CPDD, focusing on drug abuse liability. He attended professional courses in safety pharmacology, project management, and leadership, further enhancing his expertise. Additionally, he completed a teaching course at Karolinska Institute, strengthening his academic influence. 🧠💊🎓

Research Focus

Dr. Michael Swedberg’s research focuses on the pharmacology of muscarinic receptors and their potential therapeutic applications, particularly in relation to neurological and psychiatric disorders. His work has delved into muscarinic receptor agonists, with significant contributions to the understanding of their antipsychotic and antinociceptive properties. Additionally, he has explored the role of nicotinic compounds and their reinforcing effects. His research has implications for treating conditions like schizophrenia, Alzheimer’s disease, and irritable bowel syndrome. 🧠🔬💊 His studies on receptor-ligand interactions and pharmacological profiles contribute to the development of novel drugs for various neurological and gastrointestinal conditions.

Publication Top Notes

Approaches for early identification of abuse potential liability

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse

Drug Discrimination: Use in Preclinical Assessment of Abuse Liability

AZD9272 and AZD2066: Selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects

Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839

A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions

Establishment of auditory discrimination and detection of tinnitus induced by salicylic acid and intense tone exposure in the rat

Assoc Prof Dr. Djalila Boudemagh| Pharmaceutical Chemistry| Best Researcher Award-1220

Published on by Top Pharmaceutical

Assoc Prof Dr. Djalila Boudemagh,Pharmaceutical Chemistry ,Best Researcher Award

Assoc Prof Dr. Djalila Boudemagh, at Ferhat Abbas University Setif 1, Algeria

 Profile

Scopus

    

🎓Early Academic Pursuits :

Djalila Boudemagh was born on October 31, 1973, in Constantine, Algeria. Her academic journey began at the University of Mentouri Brothers Constantine 1, where she earned her Bachelor of Science (BSc) in Chemistry in 1994. She continued her studies at the same institution, receiving her Master of Science (MSc) in Material Chemistry in 2000. Her master’s thesis focused on the effect of temperature on aluminum hydroxide, magnesium hydrogen phosphate, and their mixtures. Djalila’s passion for chemistry led her to pursue a Ph.D. in material physics at Joseph Fourier University in Grenoble, France. She completed her dissertation on the synthesis and study of thermoelectric materials of the Mg2Si1-xSnx system, earning her doctorate in 2010.

🏢Professional Endeavors :

Djalila Boudemagh has dedicated over two decades to academia and research. She began her teaching career as a temporary teacher at the Chemistry Department of the University of Mentouri Brothers Constantine 1 in 1998 and later taught in the Medicine and Biology Departments until 2000. In November 2001, she joined the Department of Process Engineering at Ferhat Abbas University of Setif -1, Algeria, as an Assistant Professor. After twelve years of dedicated teaching and research, she was promoted to Associate Professor in July 2013.

In addition to her academic role, Djalila provides training and consulting services in the field of intellectual and industrial property. She has extensive experience in tutoring A-level students in various subjects, including biophysics, chemistry, the elaboration and characterization of nanoparticles, spectroscopic analysis of surfaces, and the physicochemical structure of biological macromolecules.

🔬Contributions and Research Focus :

Djalila’s research interests span a wide range of topics in chemistry and material science. Her work primarily focuses on the synthesis and application of materials and nanomaterials for health and environmental purposes, including adsorption and photocatalysis. She has made significant contributions to the field of biomaterials and composites, particularly in polymers and mineral fillers, and the extraction and isolation of bioactive molecules from plants. Her research also extends to pharmaceutical technology, water treatment, crystallization, and the development of thin films using PAPVD methods.

She has successfully supervised five Ph.D. students and twelve MSc students, guiding them through various projects related to her research interests. Djalila’s expertise in the development of nanoparticles and nanocomposites, as well as her proficiency in techniques such as sol-gel and hydrothermal methods, have established her as a prominent figure in her field.

🏅Accolades and Recognition :

In October 2019, Djalila received accreditation to direct research (HDR in Chemistry) from the Department of Chemistry at Ferhat Abbas University, Setif. This significant achievement highlights her expertise and leadership in the field of chemistry. Her research has been recognized and supported through various funded projects, including ongoing initiatives at Ferhat Abbas University Setif-1, focusing on the development of new biomaterials for tissue regeneration and environmental applications.

🌍Impact and Influence :

Djalila Boudemagh’s work has had a profound impact on both the academic and industrial sectors. Her consulting services in product development and intellectual property have benefited numerous companies, and her training programs have equipped professionals with essential skills in industrial and intellectual property. Her participation in various national and international exhibitions and fairs, such as the SIPSA FILAHA & AGROFOOD and the National Agriculture Exhibition “Mosta Expo,” showcases her commitment to sharing knowledge and fostering innovation.

🌟Legacy and Future Contributions :

Djalila Boudemagh’s legacy lies in her dedication to education, research, and the advancement of science. Her contributions to the synthesis and application of materials and nanomaterials have paved the way for future innovations in health and environmental technologies. As a member of the Mediterranean Network Act for Health and the CATI “Technology and Innovation Support Center” at Ferhat Abbas University Setif 1, she continues to collaborate with international experts and institutions, driving forward research and development in her field.

🎓Publication 

Quantification, phytochemical evaluation, and identification of pomegranate yellow peel constituents using LC-MS/MS, the effect of the solvent extract on the antioxidant, in vitro anti-inflammatory, and antibacterial activities

Elaboration of hydroxyapatite nanoparticles and chitosan/hydroxyapatite composites: a present status

Isolation, characterization, antioxidant activity, and protein-precipitating capacity of the hydrolyzable tannin punicalagin from pomegranate yellow peel (Punica granatum)

Crystal structure analysis of the Mg2Si1-xSn x system having potential thermoelectric properties at high temperature

  • Authors  :Boudemagh, D., Fruchart, D., Haettel, R., … Toboła, J., Wolfers, P.z
  • Journal   :Solid State Phenomena
  • Year        :   2011